A recent meta-analysis incorporating all 13 placebo-controlled trials with SGLT2 inhibitors involving over involving 90,000 participants and using a standardized outcome definition for kidney disease progression (a sustained ≥50% eGFR decline from randomization, ESKD or death from kidney disease) concluded that treatment with an SGLT2 inhibitor reduced the risk of kidney disease progression by 37% (relative risk 0.63, 95% CI 0.58–0.69) (50). This evidence concerns the gene SLC5A2 and kidney disorder.